New injection aims to suppress hepatitis b virus
NCT ID NCT07635186
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). Participants will receive multiple doses and be followed for 24 weeks after treatment ends.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AHB-137
- What this could lead to
- If successful, AHB-137 could offer a new treatment option that helps control chronic hepatitis B and reduces the risk of liver damage.
- What could go wrong
- This is an early-phase trial with a small number of participants. The drug may not work as expected or could cause side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
AusperBio Investigational Site
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGChongqing, Chongqing Municipality, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGXiamen, Fujian, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGGuangzhou, Guangdong, China
-
AusperBio Investigational Site
RECRUITINGGuangzhou, Guangdong, China
-
AusperBio Investigational Site
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGJiangmen, Guangdong, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGMeizhou, Guangdong, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGQingyuan, Guangdong, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGShenzhen, Guangdong, China
-
AusperBio Investigational Site
RECRUITINGShenzhen, Guangdong, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGLiuzhou, Guangxi, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGWuhan, Hubei, China
-
AusperBio Investigational Site
RECRUITINGWuhan, Hubei, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGYichang, Hubei, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGChangsha, Hunan, China
-
AusperBio Investigational Site
RECRUITINGChangsha, Hunan, China
-
AusperBio Investigational Site
RECRUITINGChangsha, Hunan, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGNanjing, Jiangsu, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGNanchang, Jiangxi, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGChangchun, Jilin, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGShenyang, Liaoning, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGShanghai, Shanghai Municipality, China
-
AusperBio Investigational Site
RECRUITINGShanghai, Shanghai Municipality, China
-
AusperBio Investigational Site
RECRUITINGShanghai, Shanghai Municipality, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGXi’an, Shanxi, China
-
AusperBio Investigational Site
RECRUITINGXi’an, Shanxi, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGChengdu, Sichuan, China
-
AusperBio Investigational Site
RECRUITINGChengdu, Sichuan, China
-
AusperBio Investigational Site
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGKunming, Yunan, China
Contact Email: •••••@•••••
-
AusperBio Investigational Site
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
-
The Second Affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data